Lg Chem, Ltd

Lg Life Sciences, Limited

Hyun Woo Joo

Young Kwan Kim

Eun Sil Choi

Sang Yun Park

Sang Dae Lee

Byung Gyu Kim

Sung Wook Kim

Chang Seok Lee

Seung Hyun Yoon

Seung Wan Kang

Seung Yup Paek

Vasily Artemov

Jin Young Jung

Ok Ku Park

Eun Jin Lee

Woo Young Cho

Su Young Yoon

Bo Kyung Seo

Myoung Yeol Kim

Min Mi Jo

Young Shin Kwak

The present invention relates to a biaryl derivative compound, which exhibits the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor and is represented by chemical formula (1), a pharmaceutical composition comprising same as an active ingredient, and a use thereof.

Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof

Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Biaryl derivative as GPR120 agonist

The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

Biaryl derivatives as GPR120 agonists

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

Thioaryl derivatives as GPR120 agonists

Growing community of inventors

Daejeon, South Korea

Hyun Woo Joo